Furthermore, according to the Genomic Classification of Cutaneous Melanoma [12], PTEN mutations, PD-1, PD-L1 and MITF genes were observed in significantly higher copy numbers in BRAF-subtype melanomas defined with the presence of hot-spot mutations; thus, these genetic alterations and the aforementioned immune mechanisms explicate the importance of applied immunotherapies or the need for predictive markers regarding therapy choice and survival. Here, CD274 is linked to melanoma.